hexarelin side effects: Frequently asked questions

Water retention from hexarelin is mediated by GH-induced sodium retention in the kidneys, not aldosterone. Reduce your dose by 25–30% or switch to every-other-day dosing rather than daily. Increasing water intake to 3–4 litres daily paradoxically reduces retention by diluting extracellular sodium concentration. If retention persists beyond 2 weeks at reduced dosing, discontinue and reassess after a 2-week washout.

Stop immediately and recheck blood pressure after 1 week off the peptide. If BP normalises, the elevation was hexarelin-induced. If it remains elevated, you've unmasked underlying hypertension that requires medical evaluation. Do not resume hexarelin until BP is controlled through lifestyle modification or medication. Cardioprotective peptides like BPC-157 can support cardiovascular health during washout periods.

You'll experience significant receptor desensitisation by month 3, rendering the peptide largely ineffective by month 4–5 despite continued dosing. GH output at month 6 will likely be 20–30% of your initial response. Stop immediately and implement a minimum 6-week washout before restarting. Consider rotating to a different GH secretagogue like CJC-1295 with ipamorelin during the washout period. Dual agonist protocols preserve receptor sensitivity better than single-peptide continuous dosing.

Do not proceed with hexarelin if baseline morning cortisol is above 20 mcg/dL or if you have diagnosed Cushing's syndrome or adrenal fatigue. Hexarelin will compound the hypercortisolism, worsening sleep disruption, immune suppression, and metabolic dysfunction. Alternative peptides like ipamorelin or MK-677 produce minimal ACTH stimulation and are safer choices for individuals with pre-existing cortisol dysregulation.

Discontinue daily dosing and implement a 14-day washout period before reintroducing the peptide. Receptor desensitization is reversible. GHS-R1a receptors are resynthesized and trafficked back to the cell surface when agonist exposure ceases. Research teams that pulse hexarelin in 5-day-on, 5-day-off cycles or 2-week-on, 2-week-off blocks maintain sensitivity across 8–12 week study periods. If your protocol requires continuous GH elevation without breaks, hexarelin is the wrong tool. Consider CJC-1295 with Ipamorelin as a more sustainable alternative. CJC-1295 extends endogenous GH pulses without direct receptor agonism, and ipamorelin demonstrates significantly slower desensitization than hexarelin.

Cease hexarelin immediately and assess prolactin levels via immunoassay. Prolactin-mediated symptoms. Reduced libido, gynecomastia in males, galactorrhea in females, menstrual irregularities. Indicate sustained hyperprolactinemia, not transient elevation. While hexarelin's prolactin spike is acute, daily dosing can prevent prolactin from returning to baseline between doses, creating a sustained elevation. If prolactin exceeds 2× the upper reference limit, a 30-day washout is recommended before introducing any GH secretagogue. For protocols requiring GH stimulation without prolactin risk, Ipamorelin or Sermorelin are safer alternatives. Neither produces clinically significant prolactin elevation at research doses.

Monitor ACTH and assess for secondary adrenal activation. Hexarelin's direct effect on corticotrophs is transient (peak at 30–60 minutes, return to baseline within 4–6 hours), but repeated daily stimulation can dysregulate the hypothalamic-pituitary-adrenal (HPA) axis in susceptible models. If cortisol remains elevated 72 hours post-cessation, the issue is likely upstream HPA dysfunction rather than residual peptide effect. Implement a structured taper rather than abrupt cessation in future protocols, and avoid dosing hexarelin more than once daily to minimize cumulative HPA load.

Reduce dosing frequency to every other day or discontinue if fasting glucose exceeds 110 mg/dL or HOMA-IR increases by >30% from baseline. GH-induced insulin resistance is reversible but can persist for 7–14 days after the last dose due to elevated IGF-1 maintaining peripheral insulin antagonism. Research teams working with diabetic or metabolically compromised models should establish glucose monitoring as a mandatory safety checkpoint at day 7, day 14, and day 28 of any hexarelin protocol. If the research question centers on metabolic health, the peptide's glucose-disrupting effects may confound the very endpoints you're measuring.